Benzbromarone

Research use only, not for human use.

A uricosuric agent and non-competitive inhibitor of xanthine oxidase (Ki=8.5 uM); also has potentcy for CYP2C9; also blocks calcium-activated chloride channel (CaCC) TMEM16A with IC50 of 9.97 uM in HEK293 cells.

A uricosuric agent and non-competitive inhibitor of xanthine oxidase (Ki=8.5 uM); also has potentcy for CYP2C9; also blocks calcium-activated chloride channel (CaCC) TMEM16A with IC50 of 9.97 uM in HEK293 cells.Other Indication Withdrawn.

Cell Cytotoxicity Assay Cell Line:HBMVECs Concentration:5 μM, 10 μM, 20 μM Incubation Time:24 h Result:Improved the viability reduced by propofol.Western Blot Analysis Cell Line:HepG2 cells Concentration:1 μM, 2 μM, 5 μM, 10 μM, 20 μM, 50 μM, 100 μM Incubation Time:2 h, 6 h, 24 h Result:Increased NRF2 protein expression in HepG2 cells exposed for 2 h, 6 h and 24 h at any concentration.Significantly accumulated the protein of NRF2 in the nuclear fraction after exposure to 100 μM at any time point.Caused an increase in the protein expression of TRX1 and TRX2.Significantly increased the ratio of oxidized TRX2 to reduced TRX2 at a concentration of 100 μM.

Animal Model:High fat diet (HFD)-induced obese (DIO) mice Dosage:25 mg/kg, 50 mg/kg Administration:Intragastric (i.g.)Result:Aggravated lipid accumulation in the liver of DIO mice.Significantly increased triglyceride accumulation and AST, ALT levels.Regulated multiple lipid metabolism genes and the expression of protein markers associated with apoptosis, endoplasmic reticulum stress, and inflammation in the liver of DIO mice.Animal Model:Cisplatin treated rats Dosage:10 mg/kg Administration:Oral gavage (p.o.)Result:Ameliorated the elevation in serum creatinine and blood urea nitrogen (BUN) levels induced by cisplatin.Counteracted oxidative stress induced by cisplatin and enhances anti-oxidant defenses in kidney.Alleviated the inflammatory events of nephrotoxicity induced by cisplatin.

MJ10061 | NSC 85433

Metabolic Enzyme/Protease

Xanthine Oxidase (XAO)

CYP2C9

Other Indications

Other Disease

3562-84-3

424.0834

C17H12Br2O3

>98% (HPLC)

DMSO: ≥ 39 mg/mL

O=C(C1=CC(Br)=C(O)C(Br)=C1)C2=C(CC)OC3=CC=CC=C23

Methanone, (3,5-dibromo-4-hydroxyphenyl)(2-ethyl-3-benzofuranyl)-

(-20℃)

With Ice Pack

≥ 2 years